Objective Our business concept focuses on development and marketing of stable fibroblast growth factors (FGFs) for medical, personal care and research use. FGFs are currently being tested therapeutically for use in cancer treatment, regenerative medicine, as well as in cosmetics. The FGF-based therapeutic approaches contribute towards promoting active and healthy ageing, which is a societal challenge common to all European countries. Another important application of FGFs is in the highly attractive cancer stem cell research with the extension to clinical applications. FGFs are being used as an essential reagent ensuring that stem cells are kept in the undifferentiated state. However, FGF instability is one of the major bottlenecks preventing wider use of FGFs. The FGFSTAB project will address this instability by computer-assisted design of multiple stabilizing mutations combined with cutting-edge molecular biology techniques. The expected outcomes of the project will be a universal protein engineering platform for designing stable FGFs and the process for manufacturing of stable FGFs that are not commercially available, even though there is a huge market for them. Added value of our innovation compared to existing solutions will be unprecedented stability, dramatic production cost reductions and the absence of harmful additives. Such FGFs will have much broader applicability than currently used natural molecules. Because of the wide range of products based on FGFs nowadays, we expect that the outcomes of the project will help us to access new high-value markets addressing global societal challenges, such as health care, bio-research, and personal care. All these market segments are characterized by the considerable size, growth and potential impact on people’s everyday lives. The phase 1 of the SME instrument will allow us to carry out well-researched feasibility study which will help us to take our business forward with confidence, and ultimately, increase our bottom line. Fields of science medical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesclinical medicineoncologymedical and health scienceshealth sciencesnutritionobesity Programme(s) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) BIOTEC-5a-2014-1 - SME boosting biotechnology-based industrial processes driving competitiveness and sustainability Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2014 Funding Scheme SME-1 - SME instrument phase 1 Coordinator ENANTIS SRO Net EU contribution € 50 000,00 Address KAMENICE 771/34 625 00 Brno Czechia See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Česko Jihovýchod Jihomoravský kraj Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
